Wells Fargo Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $200

Benzinga Newsdesk www.benzinga.com Positive 82.8%

Neg 0% Neu 0% Pos 82.8%

Wells Fargo analyst Mohit Bansal maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and raises the price target from $175 to $200.